人类疫苗佐剂市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00020517
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 199
Buy Now

【研究报告】人用疫苗佐剂市场价值预计将从2022年的15.7141亿美元增长到2030年的44.8923亿美元。进一步预计2022年至2030年人用疫苗佐剂市场的复合年增长率将达到14.0%。< br>市场洞察和分析师观点:
佐剂是疫苗配方中的重要组成部分,因为它们有助于增强人体对抗原的免疫反应,最终有助于疫苗的有效性。佐剂的范围从简单的合成小分子化合物到复杂的天然提取物和颗粒。推动人类疫苗佐剂市场增长的关键因素包括慢性病患病率的上升以及对免疫计划的日益关注。然而,制造复杂性和监管挑战阻碍了市场增长。
增长动力和限制:
慢性病患病率的上升正在推动对疫苗佐剂的需求。疫苗中添加佐剂以增强功效和身体的免疫反应。它们通过刺激更强、更持久的免疫反应来帮助提高疫苗的有效性。随着预防和管理慢性病的疫苗需求持续增长,佐剂的需求也随之增加。心血管疾病、癌症、糖尿病和呼吸系统疾病等慢性疾病在全球范围内呈上升趋势。据世界卫生组织称,与非传染性疾病相关的死亡最多的是心血管疾病,每年约有 1700 万人死于此类疾病,其次是癌症、慢性呼吸道疾病和糖尿病(包括与肾脏相关的死亡)。此外,根据世界心脏联合会的数据,高胆固醇每年导致 440 万人死亡,约 24% 的心血管相关死亡可归因于高低密度脂蛋白 (LDL) 胆固醇。因此,慢性病负担的增加导致对能够预防或控制这些疾病的疫苗的需求不断增长。
老年人口的增加也增加了对疫苗的需求。 NCBI 2023 年 1 月发布的一项研究显示,到 2050 年,美国 50 岁及以上人口将达到 22113 万人,较 2020 年的 13725 万人快速增长。 50 岁及以上人口预计将遭受至少一种慢性疾病,预计这一数字将从 2020 年的 7152 万人增加到 2050 年的 1.4266 万人,增长 99.5%。此外,预计到 2050 年,约有 1400 万人可能患有多种疾病。
肝炎的患病率也在增加。肝炎疫苗中的佐剂旨在引发强大而持久的免疫力,特别是对标准疫苗配方反应不佳的人群,例如患有基础疾病或与年龄相关的免疫衰老的人群。据世界卫生组织称,全世界有超过 3.5 亿人患有乙型或丙型肝炎。在所有类型的肝炎中,有几种可以通过疫苗接种来预防。根据世界卫生组织的一项研究,到 2030 年,低收入和中等收入国家估计可通过疫苗接种预防 450 万人因肝炎而过早死亡。因此,慢性病患病率的增加推动了人用疫苗佐剂市场的增长。
然而,人用疫苗佐剂的生产是一个复杂的过程,涉及严格的监管要求和质量控制措施。佐剂的生产需要专门的设备和设施,并严格遵守良好生产规范(GMP)和其他监管标准,以确保最终产品的纯度、安全性和功效。由于满足这些要求的资源和专业知识有限,这可能会给制造商,特别是小公司或新进入者带来重大挑战。
趋势:
精准或个性化疫苗是人类疫苗佐剂市场的增长趋势。这些疫苗针对患者疾病的特定遗传或分子特征,有助于生产适合每位患者独特免疫反应的疫苗。该技术可以潜在地提高疫苗接种的功效和安全性,从而增加人们对用于治疗癌症、传染病和自身免疫性疾病等疾病的个性化疫苗的兴趣。
生产个性化疫苗需要能够增强对这些定制疫苗的免疫反应的佐剂疫苗。佐剂对于刺激免疫系统对疫苗的特定抗原产生有针对性的强大反应至关重要。因此,对能够有效增强个性化疫苗免疫反应的佐剂的需求不断增加。近年来,人们非常重视研发工作,以确定和创造可以增强个性化疫苗免疫反应的佐剂。例如,2022 年 12 月,Moderna 和默克宣布推出 mRNA-4157/V940,这是一种在研个性化 mRNA 癌症疫苗,与 KEYTRUDA(R)(pembrolizumab)联合使用。与单独使用 KEYTRUDA 相比,mRNA-4157/V940 联合 KEYTRUDA 辅助治疗可将复发或死亡风险降低 44%。
监管机构和医疗机构认识到个性化疫苗在增强公共卫生结果方面的潜力。例如,2023 年 1 月,BioNTech 和英国政府签署了一份影响广泛的谅解备忘录 (MoU),到 2030 年为多达 10,000 名患者提供个性化 mRNA 癌症免疫疗法。这增加了该领域研究和开发计划的资金,加快个性化疫苗和佐剂监管途径的措施。因此,越来越多地开发有效改善个体化疫苗接种的免疫反应的佐剂,从而提高疫苗的功效和安全性。这一趋势推动了人类疫苗佐剂市场的大量创新和投资。
战略见解
报告细分和范围:
全球人类疫苗佐剂市场根据类型、应用和最终用户进行细分。根据类型,市场分为颗粒助剂、乳液助剂、组合助剂等。人用疫苗佐剂市场按用途分为流感佐剂、肝炎佐剂、人乳头瘤病毒佐剂(HPV)等。就最终用户而言,人用疫苗佐剂市场分为制药和生物技术公司、CMO 和 CRO 等。从地理上看,人疫苗佐剂市场分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、俄罗斯和欧洲其他地区)、亚太地区(澳大利亚、中国、日本) 、印度、韩国和亚太其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)。
细分分析:
根据类型,人用疫苗佐剂市场分为颗粒佐剂、乳液佐剂、组合佐剂等。颗粒佐剂细分市场将在 2022 年占据更大的市场份额。然而,乳液佐剂细分市场预计从 2022 年至 2030 年将在市场上实现更高的复合年增长率。颗粒佐剂由颗粒组成,通常为纳米或微米尺寸,旨在模仿病原体或细胞结构,刺激强大的免疫反应。这些佐剂增强免疫细胞对抗原的摄取并促进免疫激活。颗粒佐剂的著名例子包括铝盐(明矾),它已在人类疫苗中使用了数十年以增强抗体反应,以及新开发的产品,例如病毒样颗粒 (VLP) 和纳米颗粒佐剂。
人类疫苗佐剂市场,按类型 - 2022 年和 2030 年
按应用,人疫苗佐剂市场分为流感、肝炎、人乳头瘤病毒 (HPV) 等。流感细分市场在 2022 年占据最大市场份额,预计 2022 年至 2030 年市场复合年增长率最高。流感疫苗对于预防季节性流感爆发和潜在大流行至关重要。它们针对的是一种快速进化的病毒,需要不断更新疫苗以匹配流行的毒株。流感疫苗中使用的佐剂可增强免疫反应,特别是在老年人或免疫功能低下的个体等高危人群中。它们还支持广泛保护性、交叉反应性免疫反应的发展。
就最终用户而言,人用疫苗佐剂市场分为制药和生物技术公司、CMO 和 CRO 等。制药和生物技术公司细分市场在 2022 年占据最大份额,预计 2022 年至 2030 年复合年增长率最高。制药和生物技术公司在疫苗的研究、开发和商业化中发挥着核心作用,包括针对多种传染病和健康状况的佐剂疫苗制剂。这些公司处于疫苗创新的前沿,通过临床前和临床开发阶段推动佐剂技术、候选疫苗和佐剂疫苗配方的发现和优化。
区域分析:
从地理上看,人类疫苗佐剂市场是细分为北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,北美在全球人用疫苗佐剂市场中占据最大份额。据估计,2022-2030 年亚太地区的复合年增长率最高。
美国在北美人类疫苗佐剂市场中占有重要份额。该国的市场增长主要归因于政府医疗保健支出的增加以及对新型疫苗配方的需求激增,以更有效地治疗传染病。根据美国医疗保险和医疗补助服务中心的数据,2021 年美国国民医疗保健支出增长 2.7%,达到 4.3 万亿美元,即人均 12,914 美元。医疗卫生支出占全国GDP的18.3%。根据美国卫生与公众服务部的预测,2019-2028年国家卫生支出预计将以每年5.4%的速度增长,到2028年将达到6.2万亿美元。卫生支出的增加可能导致资金分配的增加用于疫苗的研发,刺激了对人类疫苗佐剂的需求。
根据 2020 年 7 月发表的全球疾病负担研究的新发现,非传染性疾病和传染病的负担巨大且不断增加我们。据约翰霍普金斯大学称,近二十年来,美国SARS、莱姆病、登革热、西尼罗河病毒、寨卡病毒等疾病感染病例迅速增加。此外,同一消息来源还证实,疟疾、结核病、霍乱、百日咳、流感、肺炎球菌病和淋病等重新出现的疾病的发病率有所增加。同样,根据美国疾病控制与预防中心 (CDC) 的数据,2010 年至 2022 年间,流感每年导致 100,000 至 710,000 人住院治疗,4,900 至 52,000 人死亡。根据 ICO/IARC 信息中心 2023 年 HPV 和癌症报告美国有 1.405 亿 15 岁及以上女性面临患 HPV 相关宫颈癌的风险。在美国普通人群中,预计有近 3.9% 的女性在特定时间携带宫颈 HPV16/18 感染,71.2% 的浸润性宫颈癌归因于 HPV 16 或 18。感染和重新出现的疾病推动了公司在疫苗开发方面的努力,推动了美国人类疫苗佐剂市场的增长。
美国政府努力为在该国开发和商业化药品和保健产品创造有利的环境。该国拥有多个潜在的制药和医疗器械市场参与者,包括辉瑞、诺华、波士顿科学、Integra LifeSciences、安进和雅培,其制药和医疗器械行业创新拥有各种专利。因此,各制药巨头药物开发活动的增加提振了美国的人疫苗佐剂市场。
行业发展和未来机遇:
下面列出了全球人疫苗佐剂市场主要参与者的各种举措:
2023 年 12 月,加拿大卫生部批准了 Novavax Inc 的 Nuvaxovid 新药提交的补充,作为针对 12 至 17 岁青少年的两个剂量的主要系列。2023 年 11 月,Seppic 推出了 MONTANIDE GEL P PR,这是一种水剂基于专门用于禽类注射疫苗的聚合技术的佐剂,满足禽类市场对无害性的需求。此外,MONTANIDE GEL P PR 特别稳定,可以抵抗禽类疫苗中常用的不稳定抗原介质。 2023 年 10 月,SPI Pharma Inc. 和 Q-Vant Biosciences Inc. 宣布建立合作伙伴关系,结合 Q-Vant 在可持续皂苷提取领域的领先地位技术与 SPI 在制药行业的全球影响力和服务专业知识相结合。该安排包括投资扩展 Q-Vant 专有的 100% 可持续 Q-SAP 技术,以及一项独家商业协议,以加速其皂苷佐剂在兽医和人类疫苗配方中的全球采用。 2023 年 1 月,Novavax Inc. 合作伙伴 SK Bioscience Nuvaxovid 获得韩国食品和药品安全部 (“KMFDS”) 的扩大生产和营销批准,用于 18 岁及以上成年人的增强剂。 竞争格局和主要公司:
Novartis AG、Dynavax Technologies Corp、 CSL Ltd、Seppic SA、SPI Pharma Inc、Hawaii Biotech Inc、Croda International Plc、Novavax Inc、Phibro Animal Health Corp 和 Creative Biolabs Inc 是人类疫苗佐剂市场的知名参与者。这些公司专注于新技术、现有产品的进步和地域扩张,以满足全球不断增长的消费者需求并增加其专业产品组合的产品范围。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are human vaccine adjuvants?

Adjuvants are important components in vaccine formulation as they help strengthen the body's immune response to antigens, ultimately contributing to vaccine effectiveness. Adjuvants can range from simple synthesized small molecule compounds to complicated natural extracts and particulates.

What factors drive the human vaccine adjuvants market?

Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and growing focus on immunization programs.

Who are the major players in the human vaccine adjuvants market?

The human vaccine adjuvants market majorly consists of the players, including Novartis AG, Dynavax Technologies Corp, CSL Ltd, Seppic SA, SPI Pharma Inc, Hawaii Biotech Inc, Croda International Plc, Novavax Inc, Phibro Animal Health Corp, and Creative Biolabs Inc.

What was the estimated human vaccine adjuvants market size in 2022?

The human vaccine adjuvants market was valued at US$ 1,571.41 million in 2022.

What are the growth estimates for the human vaccine adjuvants market till 2030?

The human vaccine adjuvants market is expected to be valued at US$ 4,489.23 million in 2030.

Which end users segment dominates the human vaccine adjuvants market?

In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030.

Which type segment dominates the human vaccine adjuvants market?

Based on type, the human vaccine adjuvants market is segmented into particulate adjuvant, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030.

Which application segment dominates the human vaccine adjuvants market?

By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030.

The List of Companies - Human Vaccine Adjuvants Market 

  1. Novartis AG
  2. Dynavax Technologies Corp
  3. CSL Ltd
  4. Seppic SA
  5. SPI Pharma Inc
  6. Hawaii Biotech Inc
  7. Croda International Plc
  8. Novavax Inc
  9. Phibro Animal Health Corp
  10. Creative Biolabs Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports